Hook & thesis
Hims & Hers has spent the last three months trading like a legal event rather than a consumer-health growth company. That changed on 03/09/2026, when HIMS announced a resolution with Novo Nordisk to sell Wegovy and Ozempic on its platform. The market responded violently — volume exploded and the stock ripped — and for good reason: a major source of uncertainty is gone.
The simple thesis here is this: the GLP-1 chaos that dominated headlines is fading as supply normalizes and key legal questions are resolved. Hims & Hers still owns a high-growth telehealth franchise (mental health, sexual health, dermatology, primary care) and is using M&A to accelerate international expansion. Buy a tactical mid-term position while the company proves that non-GLP-1 revenue can re-accelerate and the Eucalyptus deal begins to pay off.
What the company does and why the market should care
Hims & Hers operates a direct-to-consumer telehealth platform that connects consumers with clinicians for conditions like mental health, sexual health, dermatology and primary care. The business is attractive because it combines repeat purchase categories (prescriptions, supplements, ongoing mental-health subscriptions) with high-margin telemedicine services and a scalable digital acquisition engine.
The market should care because Hims & Hers is at an inflection point: it has resolved a material legal dispute with a major GLP-1 manufacturer and simultaneously announced a strategy to internationalize via a sizable acquisition. If management can keep growing the core non-GLP-1 categories while adding geography via Eucalyptus, the revenue base that was hammered by GLP-1 normalization can re-stabilize and re-rate.
Hard numbers that matter
- Market capitalization sits around $5.36 billion today and shares are trading at $23.50.
- Latest public quarter showed record revenue of roughly $619 million (reported on 02/23/2026) even as growth slowed; management has reiterated a 2026 revenue target of about $2.8 billion.
- Trailing earnings per share in the dataset are $0.56 with a trailing P/E in the high 30s to low 40s (reported values ~39-43).
- Price-to-sales is approximately 2.15x; enterprise value is roughly $5.795 billion with EV/sales about 2.47x.
- Free cash flow was modest but positive at about $57.4 million in the most recent annual view — not huge, but it keeps the company from burning cash while it integrates acquisitions.
- The balance sheet shows leverage: debt-to-equity is about 1.8x, so financing and deal integration are real issues to watch.
- Technicals: the stock has a 52-week range of $13.74 to $70.43. Short interest remains substantial (tens of millions of shares outstanding) and recent trading volume has been extraordinarily high, signaling both interest and risk of volatility.
Why this could work (the bull case)
1) Legal cloud cleared. The Novo Nordisk agreement removes a binary overhang that depressed multiple buyers and sellers of the stock. That alone should reduce volatility and re-open the platform to GLP-1 prescriptions under clear commercial terms.
2) GLP-1 normalization benefits retailers that can sell through the approved channels. As shortages and emergency allocations fade, telehealth providers with distribution relationships stand to regain incremental volume without the headline-driven supply panic.
3) International optionality via the Eucalyptus acquisition (up to $1.15 billion) accelerates TAM expansion into Australia, the U.K. and Germany, providing new growth vectors outside the highly contested U.S. GLP-1 market.
Valuation framing
The company currently trades at roughly $5.3B market cap and an EV of ~$5.8B. On a price-to-sales basis (~2.15x) and a trailing P/E in the high 30s, HIMS is not a deep-value name; it priced in a high-growth multiple earlier in 2025 when the stock was near $70. The pullback to the mid-$20s has removed much of the froth, but the stock still needs earnings and revenue proof to justify a higher multiple again.
Compare that to history: at the 52-week high the market priced in a near-term expectation of sustained GLP-1 contribution — the post-legal resolution environment suggests a more conservative but trackable recovery. If management hits the $2.8 billion revenue target for 2026 and non-GLP-1 categories accelerate, forward multiples could compress toward the mid-teens, implying substantial upside from current levels.
Catalysts (next 3-6 months)
- Integration progress and guidance update on the Eucalyptus acquisition (expected to close mid-2026).
- Monthly/quarterly revenue cadence showing stabilization or growth in non-GLP-1 categories after GLP-1 normalization.
- Any additional distribution agreements or manufacturer partnerships that extend telehealth prescription access.
- Quarterly earnings cadence where management reconfirms or adjusts the $2.8 billion 2026 revenue target.
Trade plan (actionable)
Thesis: The legal overhang has been removed and the company can re-focus on execution. I recommend a tactical long with explicit risk controls.
| Entry | Target | Stop | Horizon |
|---|---|---|---|
| $24.00 | $40.00 | $19.00 | Mid term (45 trading days) |
Rationale: $24.00 is a reasonable entry near recent intraday trading levels that still offers room for a pullback; $40.00 sits close to consensus analyst upside scenarios and reflects a recovery toward a more normalized multiple if execution resumes; $19.00 limits downside exposure if GLP-1 weakness or integration problems reappear.
This trade is explicitly mid-term (45 trading days): I expect the next two monthly revenue prints and any early Eucalyptus integration updates to provide the market with enough clarity to either push shares materially higher toward the $40 area or reveal execution problems that warrant exiting at the stop.
Risks and counterarguments
- GLP-1 demand could remain muted - Even with a commercial agreement in place, patient behavior and competitive pricing could keep GLP-1 volume below earlier expectations, pressuring the topline.
- Acquisition integration risk - The up to $1.15B Eucalyptus deal is sizable relative to current market cap and could strain capital allocation if synergies are slower to materialize.
- Leverage and balance-sheet pressure - Debt-to-equity of ~1.8x means the company is not asset-light; adverse macro conditions or extended margin pressure could force costly financing or dilution.
- Valuation sensitivity - Trailing P/E sits in the high 30s; any earnings miss or downward revision to 2026 guidance could cause rapid multiple compression given the history of volatility.
- Macro/commodity shocks - Energy or inflation shocks could affect consumer discretionary spending and digital ad costs, hitting customer acquisition economics.
Counterargument: Critics will point out that the stock already rallied aggressively on the Novo Nordisk news and that much of the potential upside is now priced in. Trailing multiples are still rich and GLP-1 revenues may never return to the peaks implied by last year's highs. If the market re-assigns a structurally lower multiple to telehealth names, HIMS could languish despite improved execution.
What would change my mind
I would abandon the long view if: 1) management lowers 2026 revenue guidance materially below the $2.8 billion target, 2) early integration indicators from Eucalyptus show material customer attrition or regulatory hurdles in key markets, or 3) GLP-1 supply and demand dynamics worsen again (e.g., new regulatory restrictions or price competition that meaningfully reduces gross margin on that category).
Conclusion
Hims & Hers is no longer a pure GLP-1 headline play; it is a growth-oriented telehealth platform with renewed clarity around one of its biggest overhangs and a bold push into international markets. The trade outlined above is a tactical, mid-term long: it captures upside from re-rating and integration progress while using a disciplined stop to limit downside if the recovery proves illusory.
Buy at $24.00 with a stop at $19.00 and a target of $40.00, holding for up to 45 trading days to let revenue prints and acquisition updates drive the next leg of the story.
Key near-term focus: two monthly revenue prints and the first integration signals from the Eucalyptus deal will determine whether HIMS moves from headline volatility to steady-growth multiple expansion.